Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts von Smith, Neil R, James, Neil H, Oakley, Ian, Wainwright, Anna, Copley, Clive, Kendrew, Jane, Womersley, Lynsey M, Jürgensmeier, Juliane M, Wedge, Stephen R, Barry, Simon T

Volltext

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study von Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.

Volltext